Danuglipron
Appearance
![]() | |
Clinical data | |
---|---|
Other names | PF-06882961 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
Chemical and physical data | |
Formula | C31H30FN5O4 |
Molar mass | 555.610 g·mol−1 |
3D model (JSmol) | |
| |
|
Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer[1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight[2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[3][4]
See also
[edit]References
[edit]- ^ Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956. PMID 35647711.
- ^ Medical Weight Loss
- ^ Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889. PMID 37213102.
- ^ Constantino, Annika Kim (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.